N2255
S-(4-硝基苄基)-6-硫肌苷
≥98%, Adenosine uptake inhibitor, solid
别名:
6-[(4-硝基苄基)硫代]-9-β-D-呋喃核糖基嘌呤, NBMPR, NBTI
登录 查看公司和协议定价
选择尺寸
关于此项目
经验公式（希尔记法）:
C17H17N5O6S
化学文摘社编号:
分子量:
419.41
EC 号:
MDL编号:
UNSPSC代码:
12352202
PubChem化学物质编号:
NACRES:
NA.77
产品名称
S-(4-硝基苄基)-6-硫肌苷, ≥98%, solid
方案
≥98%
表单
solid
颜色
white
mp
187-190 °C (lit.)
溶解性
0.1 M HCl: slightly soluble
0.1 M NaOH: slightly soluble
DMSO: soluble
H2O: insoluble
储存温度
2-8°C
SMILES字符串
OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n2cnc3c(SCc4ccc(cc4)[N+]([O-])=O)ncnc23
InChI
1S/C17H17N5O6S/c23-5-11-13(24)14(25)17(28-11)21-8-20-12-15(21)18-7-19-16(12)29-6-9-1-3-10(4-2-9)22(26)27/h1-4,7-8,11,13-14,17,23-25H,5-6H2/t11-,13-,14-,17-/m1/s1
InChI key
DYCJFJRCWPVDHY-LSCFUAHRSA-N
基因信息
human ... ADORA1(134), ADORA2A(135), ADORA2B(136), ADORA3(140), SLC29A1(2030)
正在寻找类似产品? 访问 产品对比指南
相关类别
一般描述
S-（4-硝基苄基）-6-硫代肌苷（NBTI）属于S6取代的6-硫代嘌呤核苷家族，可调节动物体内的核苷转运机制。它能作为腺苷转运蛋白的一种配体。NBTI的结合位点位于脑毛细血管上。它可作为共价光亲和探针用于核苷转运。
生化/生理作用
中枢神经系统和血管平滑肌中平衡核苷转运蛋白（ENT），尤其是腺苷转运蛋白的抑制剂。
有效的腺苷摄取抑制剂
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
个人防护装备
Eyeshields, Gloves, type N95 (US)
Sebastián Alarcón et al.
Cells, 9(8) (2020-08-23)
Glioblastoma multiforme is one of the most malignant types of cancer. This is mainly due to a cell subpopulation with an extremely aggressive potential, called glioblastoma stem-like cells (GSCs). These cells produce high levels of extracellular adenosine which has been
Methods Used in Adenosine Research, 268(1), 14-18 (2013)
Regulatory Function of Adenosine, 268(1), 14-18 (2012)
Robert J Paproski et al.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 51(9), 1447-1455 (2010-08-20)
(18)F-3'-Deoxy-3'-fluorothymidine ((18)F-FLT) is a PET tracer that accumulates in proliferating tissues. The current study was undertaken to determine whether equilibrative nucleoside transporter 1 (ENT1) is important for (18)F-FLT uptake in normal tissues and tumors. ENT1-knockout (ENT1(-/-)) mice were generated and
Sophie M Stief et al.
Leukemia, 34(1), 50-62 (2019-06-16)
Acute myeloid leukemia (AML) is an aggressive hematologic neoplasm resulting from the malignant transformation of myeloid progenitors. Despite intensive chemotherapy leading to initial treatment responses, relapse caused by intrinsic or acquired drug resistance represents a major challenge. Here, we report
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持